Related Experiment Videos
Cyclooxygenase-2 expression in uterine leiomyosarcomas
M R Raspollini1, G Amunni, A Villanucci
1Department of Human Pathology and Oncology, University of Florence, School of Medicine, Florence, Italy. mariarosaria.raspollini@unifi.it
Journal of Chemotherapy (Florence, Italy)
|February 11, 2005
Summary
Cyclooxygenase-2 (COX-2) is expressed in nearly half of chemoresistant uterine leiomyosarcomas. This finding suggests COX-2 may be a therapeutic target for uterine leiomyosarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cyclooxygenase-2 (COX-2) is implicated in cancer development and chemoresistance.
- COX-2 expression has been noted in various sarcomas, including uterine carcinosarcoma, osteosarcoma, and rhabdomyosarcoma.
Purpose of the Study:
- To investigate the expression of COX-2 in chemoresistant uterine leiomyosarcoma.
- To explore the potential therapeutic implications of COX-2 in uterine leiomyosarcoma.
Main Methods:
- Retrospective analysis of 30 patients with surgically treated uterine leiomyosarcoma.
- Immunohistochemical assessment of COX-2 expression in tumor tissues.
Main Results:
- COX-2 expression was detected in 13 out of 30 cases (43.3%).
- Of the 13 COX-2 positive cases, 7 were in early stages (I-II) and 6 were in advanced stages (III-IV).
Conclusions:
- COX-2 expression is present in a significant subset of chemoresistant uterine leiomyosarcomas.
- These findings suggest that targeting COX-2 could be a potential therapeutic strategy for uterine leiomyosarcoma.